Enduring Drug Eluting Stents: Update on the Current Status

AlexAbi1040M8
Alexandre Abizaid
2012-08-08

More articles by this author

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Heterotopic Treatment of the Tricuspid Valve

Tricuspid regurgitation (TR) has been associated to high morbimortality, mainly due to the development of cardiac failure, peripheral edema, ascites, kidney failure and cardiohepatic...

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Three-Year Outcomes of Mitral Valve-in-Valve Therapy with Balloon-Expandable Valves in the United States

Courtesy of Dr. Juan Manuel Pérez. Mitral Valve-in-Valve (MViV) implantation with balloon-expandable valves has become a solid alternative for patients with degenerated mitral bioprostheses. However,...